Ratings by Raymond James (Thomas Deal)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 10/8/2026 | Kymera Therapeutics | KYMR | New Coverage | Outperform (N/A) |
108.35 (104.78) |
-3.29% | Details | |
| 10/8/2026 | Odyssey Therapeutics | ODTX | New Coverage | Outperform (N/A) |
18.08 (17.17) |
-5.03% | Details | |
| 10/8/2026 | Palisade Bio Inc. | PALI | New Coverage | Outperform (N/A) |
1.48 (1.41) |
-4.73% | Details | |
| 10/8/2026 | Nektar Therapeutics | NKTR | New Coverage | Market Perform (N/A) |
40.26 (35.78) |
-11.13% | Details |
